Seegene said Monday that it has signed an agreement to supply 10 billion won ($8.4 million) worth of diagnostic kits to Biogroup-LCD, one of the top-three French inspection center associations.
Under the accord, the company will supply more than 1 million polymerase chain reaction diagnostic devices, including kits for sexual infectious diseases, female diseases and gastrointestinal infections.
“Seegene managed to be selected after competing with global companies,” the company said. “With various global companies participating in the competition, Seegene’s product has proved its excellence once again in the product-oriented French market.”
In particular, digestive tract infections are similar in symptoms, but it is challenging to examine various causes such as viruses, bacteria and parasites at the same time. Also, due to the difference between the inspection methods, the experimental space has to be separate.
The company said its digestive infectious disease screening kit is one of the unique products in the world that can accurately identify almost all causative pathogens in a single test and dramatically shorten inspection time and operating costs.
Seegene emphasized that Seegene's comprehensive test suite is quickly emerging as a new trend in the trend of the global digestive tract testing market, which is rapidly shifting to molecular diagnostic testing methods.
“In response to the new needs of the customized medical and market, which has become a recent issue, we decided to provide tests that can meet both physicians and patients,” Biogroup-LCD President Stéphane Eimer said. “In the future, the molecular diagnostic test we provide will become the key diagnostic product that will present a new standard of molecular diagnostic tests in France.”
Seegene CEO Chun Jong-yoon also said, “The molecular diagnostic business in France has been growing remarkably in recent years. In this regard, the supply contract with Biogroup-LCD is of great business importance.”
Through this partnership, the company will continue to expand business operations from France to Europe, he added.
<© Korea Biomedical Review, All rights reserved.>